Yazar "Karapinar, D. Y." seçeneğine göre listele
Listeleniyor 1 - 9 / 9
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Activated Prothrombin Complex Concentrate Prophylaxis for Haemophilia Patients with Inhibitors: Importance of Age; Toddlers vs. Young Adults(Wiley, 2015) Kavakli, K.; Balkan, C.; Karapinar, D. Y.; Karadas, N.; Ulger, Z.; Akinci, B.; Sahin, A.Öğe Feasibility of using thrombin generation assay (TGA) for monitoring of haemostasis during supplementation therapy in haemophilic patients without inhibitors(Wiley-Blackwell, 2012) Ay, Y.; Balkan, C.; Karapinar, D. Y.; Akin, M.; Bilenoglu, B.; Kavakli, K.Monitoring factor replacement treatment and observing concordance with clinical haemostasis is crucial in vital haemorrhages and major surgeries in haemophilic patients. We aimed to investigate the value of the thrombin generation assay (TGA) and thromboelastography (TEG) for monitoring haemostasis in haemophilic patients during factor replacement treatment. The study group consisted of 29 patients (21 haemophilia A, 8 haemophilia B). All the patients FVIII-inhibitor were negative. A total of 35 bleeding episodes and/or surgical interventions were evaluated. aPTT, FVIII/FIX activity, TEG and TGA tests were conducted before and after factor therapy during the bleeding episode or surgical prophylaxis of haemophilic patients. Correlations among these tests were evaluated and compared with clinical responses. No correlation was found among aPTT, factor activities and clinical outcome. There were also no correlation found between TEG parameters and clinical outcome. The only significant correlation found between TGA parameters and clinical outcome was the correlation between peak thrombin. In conclusion, we found superiority of TGA-peak thrombin over other traditional tests for monitoring haemostasis in haemophilic patients in this study.Öğe Hematuria in congenital coagulation factor deficiencies(Wiley-Blackwell, 2013) Kavakli, K.; Karadas, N.; Balkan, C.; Karapinar, D. Y.Öğe Hematuria in congenital coagulation factor deficiencies(Wiley-Blackwell, 2013) Kavakli, K.; Karadas, N.; Balkan, C.; Karapinar, D. Y.Öğe Incidence of Heparin-induced thrombocytopenia in sick children who used unfractioned heparin for prophylaxis in intensive care unit(Wiley-Blackwell, 2013) Kavakli, K.; Mursalov, G.; Karapinar, B.; Karapinar, D. Y.; Balkan, C.; Karadas, N.Öğe A novel ganciclovir desensitization protocol for a pediatric patient: A case report(Elsevier Masson, Corp Off, 2021) Severcan, E. Ulusoy; Bal, C. M.; Gulen, F.; Ozdemir, H. H.; Karapinar, D. Y.; Tanac, R.; Demir, E.A nine year-old girl, having high temperature and stomach ache symptoms, was diagnosed with primary haematophagocytic lymphohistiocytosis. During the treatment, she had neutropenic fever, dyspnea and bronchospasm. Laboratory tests revealed a 7,189,566 cytomegalovirus (CMV)-DNA copies/mL. Ganciclovir therapy was started for CMV pneumonia. At the second infusion of ganciclovir, she had dyspnea, bronchospasm, tachycardia and urticaria. Adrenaline, antihistamines and corticosteroids were administered for anaphylaxis. Treatment was replaced with valganciclovir but there was no clinical or laboratory regression. Because valganciclovir was ineffective and foscarnet could not be provided, we decided to apply desensitization with ganciclovir without performing skin tests because the reaction was anaphylactic. Total dose was 350 mg, for the patient's weight of 35 kg, according to 10 mg/kg daily dose. A (1/1000 dilution), B (1/100 dilution), C (1/10 dilution) and D (no dilution) solutions were prepared. Desensitization began with a 1/10,000(e) of the therapeutic dose, followed by 14 administrations of increasing doses every 30 minutes and lasted 6.5 hours. There was no reaction during desensitization. Patient was subsequently treated with ganciclovir every day without any problem for 21 days. After the treatment, clinical symptoms resolved and CMV-DNA copies were found < 31 IU/mL. In conclusion, we present a rare case of ganciclovir hypersensitivity (allergic or non-allergic?) and a novel protocol of ganciclovir desensitization. (C) 2021 Elsevier Masson SAS. All rights reserved.Öğe OUTCOME OF CHILDREN TREATED FOR RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA IN TURKEY(Wiley-Blackwell, 2013) Hazar, V.; Timur, C.; Aydogan, G.; Sarper, N.; Celkan, T.; Cetin, M.; Oren, H.; Turkkan, E.; Buyukavci, M.; Karapinar, D. Y.; Ozdemir, M. A.; Bor, O.; Ozbek, N.; Guler, E.; Caliskan, U.; Vergin, C.; Aksoylar, S.; Kaya, Z.Öğe Surgical experience in patients with von Willebrand disease: one center report(Wiley-Blackwell, 2014) Kavakli, K.; Balkan, C.; Karapinar, D. Y.Öğe Therapeutic Management Of Menorrhagia In Von Willebrand Disease: Single Center Experience(Wiley, 2015) Balkan, C.; Sivis, Z.; Sahin, A.; Karapinar, D. Y.; Aydinok, Y.; Kavakli, K.
